Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	AZD1480
Synonyms
Therapy Description	AZD1480 is an ATP-competitive inhibitor of JAK1 and JAK2, which reduces STAT3 activation, potentially resulting in decreased tumor growth (PMID: 22027691, PMID: 24158701) and has been also shown to inhibit ALK, LTK, FGFR1-3, RET and TRKA-C kinases (PMID: 29312610).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
AZD1480		AZD-1480	JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15	AZD1480 is an ATP-competitive inhibitor of JAK1 and JAK2, which reduces STAT3 activation, potentially resulting in decreased tumor growth (PMID: 22027691, PMID: 24158701) and has been also shown to inhibit ALK, LTK, FGFR1-3, RET and TRKA-C kinases (PMID: 29312610).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 12 of 12 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
CSF3R Q741*	hematologic cancer	predicted - sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing CSF3R Q741* were sensitive to treatment with AZD1480 in culture, demonstrating decreased cell survival (PMID: 28031554).	28031554
CSF3R T618I CSF3R Q741*	hematologic cancer	predicted - resistant	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with AZD1480 in culture (PMID: 28031554).	28031554
CSF3R T618I CSF3R W791*	hematologic cancer	predicted - resistant	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with AZD1480 in culture (PMID: 28031554).	28031554
CSF3R W791*	hematologic cancer	predicted - sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing CSF3R W791* were sensitive to treatment with AZD1480 in culture, demonstrating decreased cell survival (PMID: 28031554).	28031554
JAK2 V617F JAK2 E985K	hematologic cancer	resistant	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 G935R	hematologic cancer	resistant	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 M929I	hematologic cancer	predicted - sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 M929I double mutation were sensitive to treatment with AZD1480 in culture, demonstrating growth inhibition (PMID: 21926964).	21926964
JAK2 V617F JAK2 Y931C	hematologic cancer	resistant	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).	21926964
RET C634W	thyroid cancer	sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a thyroid cancer cell line harboring RET C634W in culture (PMID: 23056499).	23056499
RET M918T	medullary thyroid carcinoma	sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 23056499).	23056499
JAK2 V617F JAK2 I960V	hematologic cancer	resistant	AZD1480	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 R938L	hematologic cancer	resistant	AZD1480	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).	21926964

Showing 1 to 12 of 12 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Additional content available in CKB BOOST